Although most of the drugs in development over the last decade target Aβ and tau protein, therapeutic approaches that target immune cells within the brain during AD progression are attracting attention (Yiannopoulou and Papageorgiou, 2020; Salomone et al., 2012). This evidence concerns the gene MAPT and Alzheimer disease.